Amryt Pharma - AMYT Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMYT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMYT, but not buy additional shares or sell existing shares.
View AMYT analyst ratings or view top-rated stocks.

5 analysts have issued 1-year target prices for Amryt Pharma's shares. Their AMYT share price forecasts range from $14.50 to $17.00. On average, they expect the company's share price to reach $15.42 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price.
View analysts price targets for AMYT or view top-rated stocks among Wall Street analysts.

Amryt Pharma's stock was trading at $7.30 on January 1st, 2023. Since then, AMYT shares have increased by 99.3% and is now trading at $14.55.
View the best growth stocks for 2023 here.

Amryt Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 121,200 shares, an increase of 56.2% from the February 28th total of 77,600 shares. Based on an average trading volume of 646,300 shares, the short-interest ratio is presently 0.2 days.
View Amryt Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AMYT earnings forecast.

Amryt Pharma plc (NASDAQ:AMYT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT."

Amryt Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.90%), Handelsbanken Fonder AB (2.21%), Armistice Capital LLC (1.53%), Wells Fargo & Company MN (0.46%), Silverarc Capital Management LLC (0.30%) and Millennium Management LLC (0.22%).

Shares of AMYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMYT stock can currently be purchased for approximately $14.55.

Amryt Pharma (NASDAQ:AMYT) has a market capitalization of $930.62 million and generates $222.54 million in revenue each year. The company earns $1 million in net income (profit) each year or ($0.06) on an earnings per share basis.

The company employs 2,020 workers across the globe.

Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The official website for the company is www.amrytpharma.com. The company can be reached via phone at 353-1518-0200 or via email at ir@amrytpharma.com.